Practical Insights and Challenges in the Rational Use of Targeted Agents in Metastatic Clear Cell Renal Carcinoma
- Swati Andhavarapu
- Winston Tan
Abstract
Renal cell carcinoma (RCC) accounts for approximately 4% of all primary cancers diagnosed in the United States with an estimated 13,000 deaths in 2010. Metastatic disease is the initial presentation in approximately 30% of the patients. Until 2006, immunotherapy with Interferon-? and Interleukin-2 represented the primary treatment of advanced RCC but better understanding of the pathogenesis and molecular biology of RCC paved the way for targeted molecular therapies. Six molecular targeted agents have been approved for the treatment of metastatic renal cell carcinoma (mRCC). This review summarizes the approved targeted agents, their toxicities and practical insights into the treatment of mRCC.
- Full Text:
PDF
- DOI:10.5539/cco.v1n1p1
Journal Metrics
Google-based Impact Factor (2018): 3.94
h-index (August 2018): 8
i10-index (August 2018): 6
h5-index (August 2018): N/A
h5-median(August 2018): N/A
(The data was calculated based on Google Scholar Citations. Click Here to Learn More. )
Index
Contact
- Lexie GreyEditorial Assistant
- cco@ccsenet.org